DrugsTreatingRheumatism

1、（osteoarthritis, OS ） glycosides (uricosuric drugs, Analgesics reduce pain A heterogeneous collection of agents grouped together by use and convention. They are the mainstay of treatment for rheumatoid arthritis. Their diverse mechanisms of action are incompletely understood. They reduce joint swell

2、ing and pain, decrease acute-phase markers, limit progressive joint damage, and improve function.ACR50 responses in trials of DMARDs and biological agentsACR50=50% improvements in five of the seven measures of American College of Rheumatology criteria. Error bars=95% CIs. Short-term GCs reduce synov

3、itis Long term GCs decrease joint damage AzathioprineInhibits monophosphate dehydrogenase and blocks synthesis of guanosine nucleotides and proliferation of T cells and B cellsUsed for induction and maintenance treatment of lupus nephritis, also useful agent for other systemic features of systemic l

4、upus erythematosus, usual dose 0.53 g per day Findings from ALMS (370 patients) study showed no significant difference between cyclophosphamide and mycophenolate as induction agents for lupus nephritis.Targeted biological agents available and in present or previous clinical trials of systemic lupus erythematosus (SLE)pDC=plasmacytoid dendritic cell. BLys=B-lymphocyte stimulat